Dolby Laboratories price target lowered to $85 from $95 at Rosenblatt

Rosenblatt cut its price target on Dolby Laboratories to $85 from $95 but kept a Buy rating, noting macroeconomic headwinds despite a strong fiscal Q4; the new target aligns with InvestingPro’s fair-value view as DLB trades near its 52-week low of $64.02. Dolby beat expectations with adjusted EPS of $0.99 versus $0.70 and revenue of $307M versus $305.8M, delivered an 88.5% gross margin, reported more cash than debt, and raised guidance, yet shares fell about 2.2% amid investor concerns. Rosenblatt highlighted scaling of Atmos and Vision, potential streaming TAM expansion, an 11-year dividend increase (2.03% yield), and a PEG of 0.97/19x 2026 EPS, signaling potential long-term value for patient investors even as near-term skepticism persists.

Analysis

Rosenblatt reduced its price target on Dolby Laboratories to $85 from $95 while keeping a Buy rating, a move that balances confidence in the company with stated macroeconomic headwinds; the stock trades near its 52-week low of $64.02. Dolby reported fiscal Q4 adjusted EPS of $0.99 versus $0.70 expected and revenue of $307 million versus $305.8 million consensus, and the company raised guidance despite shares falling about 2.2% on investor concerns.

Dolby’s 88.5% gross margin and a balance sheet with more cash than debt underline strong unit economics and financial flexibility, and the firm’s 11-year streak of dividend increases (2.03% yield) supports an income-oriented, long-term thesis. Rosenblatt highlights scaling of Atmos and Vision and potential streaming TAM expansion as the primary growth levers, while valuation metrics cited — a $85 target implying ~19x 2026 EPS and a PEG of 0.97 — suggest the market is pricing in moderate growth expectations.

Near-term risk stems from macro sensitivity and the market’s reaction to guidance details rather than headline beats; execution on Atmos/Vision adoption and clearer revenue cadence for streaming-related opportunities will be the critical catalysts to re-rate the stock. The combination of a conservative near-term tone and attractive medium-term valuation frames this as a selectively patient opportunity where monitoring forward guidance and execution is essential.

Key Decisions for Investors

• Consider initiating a small, staged position given the 19x 2026 EPS implication, PEG ~0.97 and strong margin profile, but size exposure for a multi-year horizon
• Require clearer incremental guidance or specific KPIs on Atmos/Vision scaling and streaming TAM adoption before materially increasing position size
• If adding, use limit buys near the low-$60s to mid-$60s area around the 52-week low ($64.02) and consider phased accumulation to mitigate macro risk
• Monitor cash/debt dynamics and any capital return or M&A announcements as potential upside catalysts and set risk limits in case macro concerns depress near-term sentiment